MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 5, 2016, Pages 1363-1368

  Cavalli, Giulio ^a,b   Hayashi, Masahiro ^a   Jin, Ying ^a,c   Yorgov, Daniel ^c   Santorico, Stephanie A ^a,d   Holcomb, Cherie ^e   Rastrou, Melinda ^e   Erlich, Henry ^e   Tengesdal, Isak W ^a   Dagna, Lorenzo ^b   Neff, C Preston ^a   Palmer, Brent E ^a   Spritz, Richard A ^a,c   Dinarello, Charles A ^a,f  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c University of Colorado Denver and Children s Hospital Colorado   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e ROCHE MOLECULAR SYSTEMS   (United States)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigen presentation; Autoimmunity; Inflammation; MHC transcription; Vitiligo

Indexed keywords

AUTOANTIGEN; DECTIN 1; GAMMA INTERFERON; HLA DQ ANTIGEN; HLA DQA1 ANTIGEN; HLA DR ANTIGEN; HLA DRB1 ANTIGEN; INTERLEUKIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE; RNA; TOLL LIKE RECEPTOR; CYTOKINE; HLA ANTIGEN CLASS 2;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANDIDA ALBICANS; CAUCASIAN; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; STAPHYLOCOCCUS EPIDERMIDIS; VITILIGO; AUTOIMMUNE DISEASE; BIOSYNTHESIS; ENHANCER REGION; IMMUNOLOGY;

AUTOIMMUNE DISEASES; CYTOKINES; ENHANCER ELEMENTS, GENETIC; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; VITILIGO;

EID: 84956649472     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1523482113     Document Type: Article

References (42)

1. Marrack P, Kappler J, Kotzin BL (2001) Autoimmune disease: Why and where it occurs. Nat Med 7(8):899-905.
2. Jacobson DL, Gange SJ, Rose NR, Graham NM (1997) Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 84(3):223-243.
3. Ezzedine K, et al.; Vitiligo Global Issue Consensus Conference Panelists (2012) Revised classification/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 25(3):E1-E13.
4. Jin Y, et al. (2010) Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med 362(18):1686-1697.
5. Jin Y, et al. (2010) Common variants in FOXP1 are associated with generalized vitiligo. Nat Genet 42(7):576-578.
6. Jin Y, et al. (2012) Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet 44(6):676-680.
7. Horton R, et al. (2004) Gene map of the extended human MHC. Nat Rev Genet 5(12):889-899.
8. Shiina T, Hosomichi K, Inoko H, Kulski JK (2009) The HLA genomic loci map: Expression, interaction, diversity and disease. J Hum Genet 54(1):15-39.
9. Kellis M, et al. (2014) Defining functional DNA elements in the human genome. Proc Natl Acad Sci USA 111(17):6131-6138.
10. Hon GC, Hawkins RD, Ren B (2009) Predictive chromatin signatures in the mammalian genome. Hum Mol Genet 18(R2):R195-R201.
11. Creyghton MP, et al. (2010) Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci USA 107(50):21931-21936.
12. Shlyueva D, Stampfel G, Stark A (2014) Transcriptional enhancers: From properties to genome-wide predictions. Nat Rev Genet 15(4):272-286.
13. Ward LD, Kellis M (2012) HaploReg: A resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 40(Database issue):D930-D934.
14. Kundaje A, et al.; Roadmap Epigenomics Consortium (2015) Integrative analysis of 111 reference human epigenomes. Nature 518(7539):317-330.
15. Consortium G; GTEx Consortium (2015) Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science 348(6235):648-660.
16. Netea MG, et al. (2002) The role of endogenous interleukin (IL)-18, IL-12, IL-1beta, and tumor necrosis factor-alpha in the production of interferon-gamma induced by Candida albicans in human whole-blood cultures. J Infect Dis 185(7):963-970.
17. Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol 75(2):163-189.
18. Majumder P, Boss JM (2011) DNA methylation dysregulates and silences the HLA-DQ locus by altering chromatin architecture. Genes Immun 12(4):291-299.
19. Yan ZH, et al. (2012) Relationship between HLA-DR gene polymorphisms and outcomes of hepatitis B viral infections: A meta-analysis. World J Gastroenterol 18(24):3119-3128.
20. Gusev A, et al.; Schizophrenia Working Group of the Psychiatric Genomics Consortium; SWE-SCZ Consortium; Schizophrenia Working Group of the Psychiatric Genomics Consortium; SWE-SCZ Consortium (2014) Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. Am J Hum Genet 95(5):535-552.
21. Finucane HK, et al.; ReproGen Consortium; Schizophrenia Working Group of the Psychiatric Genomics Consortium; RACI Consortium (2015) Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat Genet 47(11):1228-1235.
22. Farh KK, et al. (2015) Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518(7539):337-343.
23. Thomas R, et al. (2012) A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection. J Virol 86(12):6979-6985.
24. Petersdorf EW, et al. (2015) High HLA-DP expression and graft-versus-host disease. N Engl J Med 373(7):599-609.
25. Petersdorf EW, et al.; International Histocompatibility Working Group in Hematopoietic Cell Transplantation (2014) HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation. Blood 124(26):3996-4003.
26. Apps R, et al. (2013) Influence of HLA-C expression level on HIV control. Science 340(6128):87-91.
27. Harris JE, et al. (2012) A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin. J Invest Dermatol 132(7):1869-1876.
28. Levandowski CB, et al. (2013) NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1p processing via the NLRP1 inflammasome. Proc Natl Acad Sci USA 110(8):2952-2956.
29. Cavalli G, Dinarello CA (2015) Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) 54(12):2134-2144.
30. Maruthappu T, Leandro M, Morris SD (2013) Deterioration of vitiligo and new onset of halo naevi observed in two patients receiving adalimumab. Dermatol Ther (Heidelb) 26(4):370-372.
31. Alghamdi KM, Khurrum H, Rikabi A (2011) Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab. J Cutan Med Surg 15(5):280-284.
32. Alghamdi KM, Khurrum H, Taieb A, Ezzedine K (2012) Treatment of generalized vitiligo with anti-TNF-a agents. J Drugs Dermatol 11(4):534-539.
33. Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA (2009) Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 38(5):328-331.
34. Ranges GE, Figari IS, Espevik T, Palladino MA, Jr (1987) Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med 166(4):991-998.
35. Carvalho CL, Ortigosa LC (2014) Segmental vitiligo after infliximab use for rheumatoid arthritis-A case report. An Bras Dermatol 89(1):154-156.
36. Kimachi K, Croft M, Grey HM (1997) The minimal number of antigen-major histocompatibility complex class II complexes required for activation of naive and primed T cells. Eur J Immunol 27(12):3310-3317.
37. Viola A, Lanzavecchia A (1996) T cell activation determined by T cell receptor number and tunable thresholds. Science 273(5271):104-106.
38. Freitas AA, Rocha B (1999) Peripheral T cell survival. Curr Opin Immunol 11(2):152-156.
39. Bradley LM, Dalton DK, Croft M (1996) A direct role for IFN-gamma in regulation of Th1 cell development. J Immunol 157(4):1350-1358.
40. Bentley G, et al. (2009) High-resolution, high-throughput HLA genotyping by next-generation sequencing. Tissue Antigens 74(5):393-403.
41. Holcomb CL, et al. (2011) A multi-site study using high-resolution HLA genotyping by next generation sequencing. Tissue Antigens 77(3):206-217.
42. Wang J, et al. (2012) Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. Genome Res 22(9):1798-1812.